INDEMNIFICATION AGREEMENTIndemnification Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 20 between Editas Medicine, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
ContractEditas Medicine, Inc. • January 4th, 2016 • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
FORM OF INDEMNIFICATION AGREEMENTForm of Indemnification Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 201 between Editas Medicine, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
EDITAS MEDICINE, INC. Incentive Stock Option Agreement Granted Under 2013 Stock Incentive PlanIncentive Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
EDITAS MEDICINE, INC. Nonstatutory Stock Option Agreement Granted Under 2013 Stock Incentive Plan (Early Exercise)Nonstatutory Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
EDITAS MEDICINE, INC. Restricted Stock Agreement Granted Under 2013 Stock Incentive PlanRestricted Stock Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
EDITAS MEDICINE, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
EDITAS MEDICINE, INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances)
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
SUBLEASELease • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
June 8, 2015 Andrew A. F. Hack, M.D., Ph.D. Apt. 3AB New York, NY 10025 Dear Andrew:Editas Medicine, Inc. • January 4th, 2016 • Biological products, (no disgnostic substances) • Massachusetts
On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
June 12, 2014Invention and Non-Disclosure Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
On behalf of Editas Medicine, Inc. (the “Company”), I am pleased to offer you employment with the Company. The purpose of this letter agreement (the Agreement”) is to set forth the terms of your employment with the Company, should you accept our offer.
Real Estate License AgreementSublease Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS SUBLEASE AGREEMENT (this “Sublease”) is entered as of the Effective Date by and between Sublandlord and Subtenant on the basis of the following facts, understandings and intentions:
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), effective as of May 26, 2015 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation, having a principal place of business at 300 Third Street, First Floor, Cambridge, MA 02142 (“Editas”), and Juno Therapeutics, Inc., a Delaware corporation, having a place of business at 307 Westlake Avenue North, Suite 300, Seattle, WA 98109 (“Juno”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • California
This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of the date set forth above (the “Effective Date”) by and between SILICON VALLEY BANK (“Bank”), and the borrower named above (“Borrower”). Capitalized terms used but not otherwise defined herein shall have the meanings given them on Schedule C, The parties agree as follows:
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: A221317 MGH Case Nos: [**]Patent License Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“Agreement”) is made as of the 29th day of August, 2014 (“Effective Date”), by and between Editas Medicine, Inc., a Delaware corporation, with its principal place of business located at 300 Third Street, Cambridge, MA 02142 (“Company”), and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS Agreement is entered into this 10th day of October, 2014 (“Effective Date”) between DUKE UNIVERSITY, a nonprofit educational and research institution organized under the laws of North Carolina (“DUKE”), having a place of business at Durham, North Carolina 27710, and Editas Medicine, Inc., a corporation organized under the laws of the State of Delaware (“Licensee”), having its principal office at 300 Third Street, First Floor, Cambridge, MA 02142. Duke or Licensee may be referred to herein individually as a “Party” and collectively as the “Parties”.
EDITAS MEDICINE, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 4, 2015Investors’ Rights Agreement • January 4th, 2016 • Editas Medicine, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 4th day of August, 2015, by and among Editas Medicine, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Editas Medicine, Inc. • January 4th, 2016 • Biological products, (no disgnostic substances)
